Back

Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation management: from anticoagulation to SGLT2 inhibitors Prevalence and Incidence of Atrial Fibrillation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Kushal Banerjee

London (United Kingdom of Great Britain & Northern Ireland)

2 More presentations in this session

Presentation thumbnail
Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease
Doctor S. Im (Pusan, KR)
Abstract Slides Video
Presentation thumbnail
Impact of cardiac damage on cardioversion success in patients with atrial fibrillation and heart failure with preserved ejection fraction
Doctor P. Wilke (Duesseldorf, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation management: from anticoagulation to SGLT2 inhibitors

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved ejection fraction - A meta-analysis of randomised-controlled trials
thumbnail
Congress Presentation
Sglt2 inhibitors vs. dpp-4 inhibitors and glp-1 receptor agonists on atrial fibrillation incidence in type 2 diabetes: a meta-analysis
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources